Ceftazidime-Avibactam Versus Polymyxin-Based Combination Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48-Endemic Region

• প্রধান লেখক: Rıdvan Dumlu (লেখক), Meyha Şahin (লেখক), Okan Derin (লেখক), Özlem Gül (লেখক), Sedef Başgönül (লেখক), Rehile Zengin (লেখক), Çiğdem Arabacı (লেখক), Funda Şimşek (লেখক), Serap Gençer (লেখক), Ayşe Sesin Kocagöz (লেখক), Ali Mert (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2024-10-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

<b>Background</b>: Ceftazidime-avibactam (CAZ-AVI) is recommended as first-line treatment for Oxacillinase-48 (OXA-48) β-Lactamase-producing carbapenem-resistant Enterobacterales (CRE) infections, while polymyxin-based combination therapies (PBCTs) are used as a last resort when CAZ-AVI...